The pathological diagnosis of neuroendocrine tumors: Common questions and tentative answers

Virchows Archiv

Volumn 458, Issue 4, 2011, Pages 393-402

  Volante, Marco ^a   Righi, Luisella ^a   Berruti, Alfredo ^a   Rindi, Guido ^b   Papotti, Mauro ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Carcinoid; Classification; Ki 67; Mixed exocrine endocrine carcinoma; Neuroendocrine tumor; Small cell carcinoma

Indexed keywords

KI 67 ANTIGEN; TUMOR MARKER;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; HUMAN; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION;

HUMANS; NEUROENDOCRINE TUMORS; WORLD HEALTH ORGANIZATION;

EID: 79956216573     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-011-1060-7     Document Type: Review

References (53)

1. Yao JC, Hassan M, Phan A et al (2008) One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol 26(18):3063-3072
2. Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E (2008) Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst 100 (18):1282-1289
3. Righi L, Volante M, Rapa I, Scagliotti GV, Papotti M (2007) Neuroendocrine tumours of the lung. A review of relevant pathological and molecular data. Virchows Arch 451(Suppl 1):S51-S59
4. Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9(1):61-72
5. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39 (6):707-712
6. Ploeckinger U, Kloeppel G, Wiedenmann B, Lohmann R (2009) The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology 90(4):349-363
7. Kloppel G, Couvelard A, Perren A et al (2009) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 90(2):162-166
8. Klimstra DS, Modlin IR, Adsay NV et al (2010) Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 34(3):300-313
9. Solcia E, Kloppel G, Sobin L (2000) Histological typing of endocrine tumors. World Health Organization International Histological Classification of Tumors. Springer, Berlin
10. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (2004) Tumours of the lung, pleura, thymus and heart. World Health Organization Classification Tumours. Pathology and genetics. IARC Press, Lyon
11. Bosman FT, Carneiro F, Hruban RH, Theise ND (2010) Tumors of the digestive system. World Health Organization Classification of Tumours. Pathology and genetics. IARC Press, Lyon
12. DeLellis RA, Lloyd RV, Heitz PU (2004) Tumors of endocrine organs. World Health Organization Classification of Tumors. Pathology and genetics. IARC Press, Lyon
13. Asamura H, Kameya T, Matsuno Y et al (2006) Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 24 (1):70-76 (Pubitemid 46630496)
14. Righi L, Volante M, Tavaglione V et al (2010) Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Ann Oncol 21(3):548-555
15. Skov BG, Krasnik M, Lantuejoul S, Skov T, Brambilla E (2008) Reclassification of neuroendocrine tumors improves the separation of carcinoids and the prediction of survival. J Thorac Oncol 3 (12):1410-1415
16. Cheuk W, Chan JK (2001) Thyroid transcription factor-1 is of limited value in practical distinction between pulmonary and extrapulmonary small cell carcinomas. Am J Surg Pathol 25(4):545-546 (Pubitemid 32240900)
17. Rindi G, Kloppel G, Alhman H et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449(4):395-401 (Pubitemid 44451313)
18. Rindi G, Kloppel G, Couvelard A et al (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451(4):757-762 (Pubitemid 47497934)
19. Tsuta K, Raso MG, Kalhor N, Liu DD, Wistuba II, Moran CA (2011) Histologic features of low- and intermediate-grade neuroendocrine carcinoma (typical and atypical carcinoid tumors) of the lung. Lung Cancer 71(1):34-41
20. Rami-Porta R, Ball D, Crowley J et al (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2(7):593-602 (Pubitemid 47171780)
21. Klöppel G, Rindi G, Perren A, Komminoth P, Klimstra DS (2010) The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch 456(6):595-597
22. Pape UF, Jann H, Muller-Nordhorn J et al (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113 (2):256-265
23. Travis WD, Giroux DJ, Chansky K et al (2008) The IASLC lung cancer staging project: proposals for the inclusion of bronchopulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 3(11):1213-1223
24. Scarpa A, Mantovani W, Capelli P et al (2010) Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 23(6):824-833
25. Couvelard A, Deschamps L, Ravaud P et al (2009) Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. Mod Pathol 22 (2):273-281
26. Srivastava A, Hornick JL (2009) Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. Am J Surg Pathol 33(4):626-632
27. La Rosa S, Rigoli E, Uccella S, Chiaravalli AM, Capella C (2004) CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors. Virchows Arch 445(3):248-254 (Pubitemid 39286892)
28. Schmitt AM, Riniker F, Anlauf M et al (2008) Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol 32(3):420-425 (Pubitemid 351398934)
29. Jamali M, Chetty R (2008) Predicting prognosis in gastroenteropancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol 19(4):282-288
30. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B (2008) Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 14 (23):7798-7803
31. Brizzi MP, Berruti A, Ferrero A et al (2009) Continuous 5- fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer 9:388
32. Oberg K, Akerstrom G, Rindi G, Jelic S (2010) Neuroendocrine gastroenteropancreatic tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v223-v227
33. Oberg K, Astrup L, Eriksson B et al (2004) Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part Igeneral overview. Acta Oncol 43(7):617-625 (Pubitemid 39563934)
34. Kaltsas GA, Besser GM, Grossman AB (2004) The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25(3):458-511 (Pubitemid 38780668)
35. Vilar E, Salazar R, Perez-Garcia J, Cortes J, Oberg K, Tabernero J (2007) Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer 14 (2):221-232 (Pubitemid 47242624)
36. O'Toole D, Couvelard A, Rebours Vet al (2010) Molecular markers associated with response to chemotherapy in gastro-enteropancreatic neuroendocrine tumors (GEP). Endocr Relat Cancer 17 (4):847-856
37. Klöppel G, Anlauf M, Raffel A, Perren A, Knoefel WT (2008) Adult diffuse nesidioblastosis: genetically or environmentally induced? Hum Pathol 39(1):3-8
38. Tang LH, Shia J, Soslow RA et al (2008) Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol 32(10):1429-1443
39. Volante M, Righi L, Asioli S, Bussolati G, Papotti M (2007) Goblet cell carcinoids and other mixed neuroendocrine/nonneuroendocrine neoplasms. Virchows Arch 451(Suppl 1):S61-S69 (Pubitemid 47283379)
40. Tavassoli FA, Devilee P (2003) Tumours of the breast and female genital organs. World Health Organization Classification of Tumours. Pathology and genetics. IARC Press, Lyon
41. Righi L, Sapino A, Marchio C, Papotti M, Bussolati G (2010) Neuroendocrine differentiation in breast cancer: established facts and unresolved problems. Semin Diagn Pathol 27(1):69-76
42. Volante M, Rindi G, Papotti M (2006) The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumours: a comment on concepts and classification of mixed exocrineendocrine neoplasms. Virchows Arch 449(5):499-506 (Pubitemid 44722317)
43. Berruti A, Mosca A, Porpiglia F et al (2007) Chromogranin A expression in patients with hormone naive prostate cancer predicts the development of hormone refractory disease. J Urol 178(3 Pt 1):838-843 (Pubitemid 47211059)
44. Berruti A, Bollito E, Cracco CM et al (2010) The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy. Prostate 70(7):718-726
45. Sciarra A, Monti S, Gentile V et al (2003) Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 55(3):168-179 (Pubitemid 36532395)
46. Yuan TC, Veeramani S, Lin MF (2007) Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 14(3):531-547 (Pubitemid 350074046)
47. Long KB, Srivastava A, Hirsch MS, Hornick JL (2010) PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol 34(5):723-729
48. Durante C, Boukheris H, Dromain C et al (2009) Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer 16(2):585-597
49. Volante M, Brizzi MP, Faggiano A et al (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20(11):1172-1182 (Pubitemid 47609066)
50. Yao JC, Phan AT, Chang DZ et al (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediategrade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26(26):4311-4318
51. Missiaglia E, Dalai I, Barbi S et al (2010) Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 28(2):245-255
52. Righi L, Volante M, Rapa I et al (2010) Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer 17(4):977-987
53. Ceppi P, Volante M, Ferrero A et al (2008) Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 14(4):1059-1064 (Pubitemid 351302551)